21.20.Z - Manufacture of medicines and other pharmaceutical products
21.10.Z - Manufacture of basic pharmaceutical substances
46.46.Z - Wholesale of pharmaceutical goods
47.91.Z - Retail sale via mail order houses or via Internet
71.20.A - Food quality testing and analysis
71.20.B - Other technical testing and analysis
72.11.Z - Research and experimental development on biotechnology
72.19.Z - Other research and experimental development on natural sciences and engineering
73.20.Z - Market research and public opinion polling
74.90.Z - Other professional, scientific and technical activities not elsewhere classified
2021 | 2022 | 2023 | ||
---|---|---|---|---|
M PLN | M PLN | M PLN | % | |
Profit (loss) on sale | 1,9 | 2,2 | 1,1 | -47,7 |
Gross profit (loss) | 1,7 | 1,7 | 0,8 | -54 |
EBITDA | 1,9 | 2 | 1,1 | -43,1 |
Short time liabilities | 2,6 | 1,2 | 0,9 | -28 |
Other operating costs | 0,4 | 0,5 | 0,4 | -10,5 |
Equity capital | 5,1 | 6,6 | 7,4 | 12 |
Operating profit (EBIT) | 1,7 | 1,8 | 0,9 | -52,1 |
Assets | 7,8 | 7,9 | 8,4 | 6,8 |
Net profit (loss) | 1,5 | 1,5 | 0,8 | -47,3 |
Cash | 1,9 | 1 | 1,2 | 18,3 |
Net income from sale | 13,3 | 14,9 | 14,7 | -1,4 |
Liabilities and provisions for liabilities | 2,7 | 1,3 | 1 | -20,2 |
Working assets | 7,1 | 7 | 7,7 | 9,4 |
Other income costs | 0,2 | 0,1 | 0,1 | 64,5 |
Depreciation | 0,1 | 0,2 | 0,3 | 52 |
% | % | % | p.p. | |
Profitability of capital | 30 | 22,7 | 10,7 | -12 |
Equity capital to total assets | 65,6 | 83,8 | 87,9 | 4,1 |
Gross profit margin | 13,1 | 11,6 | 5,4 | -6,2 |
EBITDA Margin | 14,2 | 13,1 | 7,6 | -5,5 |
Days | Days | Days | Days | |
Short term commitment turnover cycle | 72 | 30 | 22 | -8 |
Current financial liquidity indicator | 2.7425143718719482 | 5.841043949127197 | 8.87010383605957 | 3,1 |
Net dept to EBITDA | -0.12610141932964325 | -0.45244818925857544 | -0.9846277236938477 | -0,5 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane